STOCK TITAN

Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference

Satellos (NASDAQ: MSLE) will present at the Bloom Burton & Co. Healthcare Investor Conference on April 21, 2026, in Toronto.

(Moderate)
(Neutral)
Tags

Satellos (NASDAQ: MSLE) will present at the Bloom Burton & Co. Healthcare Investor Conference on April 21, 2026, in Toronto. CEO Frank Gleeson will present on April 21 at 11:30 a.m. ET and CEO Gleeson and CFO Liz Williams will hold one-on-one meetings April 21-22.

The live presentation will be available via webcast on the company’s Events and Presentations page, with a replay accessible after the session.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.
Argus Apr 9 session
-0.80% close to close Open Argus
Details

News Market Reaction – MSLE

On Apr 9, the day this news came out, MSLE closed 0.80% below the previous close.

Data tracked by StockTitan Argus for the Apr 9 session.

Market Context

This announcement highlights Satellos’ ongoing investor outreach, with a Bloom Burton conference pre...
Analysis

This announcement highlights Satellos’ ongoing investor outreach, with a Bloom Burton conference presentation and one-on-one meetings on April 21–22, 2026. It follows a series of updates on SAT-3247 clinical progress and the company’s 2025 financial results, which included a recent Nasdaq listing and equity financing. Investors may focus on how management frames trial status, cash runway, and upcoming milestones during the presentation and subsequent webcast replay.

Key Figures

Conference dates: April 21–22, 2026 Presentation date: April 21, 2026 Presentation time: 11:30 a.m. ET
Conference dates
April 21–22, 2026
Bloom Burton & Co. Healthcare Investor Conference
Presentation date
April 21, 2026
Satellos CEO conference presentation
Presentation time
11:30 a.m. ET
Bloom Burton conference presentation slot

Historical Context

5 past events · Latest: Mar 27
5 events
  1. Mar 27

    Earnings and financing

    24h Move
    -10.7%

    2025 results, US$57.2M financing, Nasdaq listing, Phase 2 initiations.

  2. Mar 10

    Clinical data update

    24h Move
    -18.1%

    Interim SAT-3247 clinical and biomarker data in DMD and FSHD models.

  3. Feb 24

    Conference presentations

    24h Move
    +0.6%

    Planned oral and poster presentations at 2026 MDA conference.

  4. Feb 18

    KOL event announcement

    24h Move
    -1.5%

    Virtual KOL event on DMD and SAT-3247 program details.

  5. Feb 17

    Investor conferences

    24h Move
    -0.6%

    Participation in multiple investor conferences with webcasts and meetings.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

TORONTO, April 09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“ Satellos ” or the “ Company ”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will participate in the Bloom Burton & Co. Healthcare Investor Conference taking place April 21-22, 2026, at the Metro Toronto Convention Centre in Toronto, Canada.

Satellos Co-founder and CEO Frank Gleeson will provide a presentation on April 21 and along with Liz Williams, Chief Financial Officer, will participate in one-on-one meetings during the conference.

2026 Bloom Burton & Co. Healthcare Investor Conference
Format: Presentation and webcast
Presenter: Frank Gleeson, President and CEO
Date: Tuesday, April 21
Time: 11:30 a.m. ET
Location: Metro Toronto Convention Centre

The presentation will be available via live webcast on the Events and Presentations page in the Investors section of the Company’s website, and a replay will be available following the presentation.

ABOUT SATELLOS BIOSCIENCE INC.

Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed SAT-3247, a first-of-its-kind, orally administered small molecule therapy designed to address deficits in muscle repair and regeneration. SAT-3247 is being evaluated as a potential disease-modifying treatment, initially for DMD, in two Phase II clinical trials: BASECAMP in pediatrics and TRAILHEAD in adults. SAT-3247 targets AAK1, a key protein that Satellos has identified as capable of helping restore the body’s natural muscle repair and regeneration biology, a fundamental stem cell driven process that is disrupted in DMD and other degenerative conditions. By addressing the loss in a dystrophin-independent manner, SAT-3247 may re-establish the biochemical signals needed to support muscle regeneration, with potential broad applicability as either a stand-alone or adjunctive therapy. Satellos has identified additional muscle diseases and injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and plans to pursue these opportunities in future clinical development. For more information, visit www.satellos.com.

CONTACTS

Investors: Dan Ferry, LifeSci Advisors, daniel@lifesciadvisors.com
Media: Emily Williams, Senior Director of Communications, media@satellos.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Satellos (MSLE) present at the Bloom Burton Healthcare Investor Conference in 2026?

Satellos will present on April 21, 2026, at 11:30 a.m. ET. According to the company, CEO Frank Gleeson will deliver the presentation at the Metro Toronto Convention Centre, with investor one-on-one meetings involving the CEO and CFO on April 21-22.

How can investors watch the Satellos (MSLE) presentation on April 21, 2026?

Investors can watch via a live webcast on the company’s Events and Presentations page. According to the company, a replay will also be posted after the live presentation for on-demand viewing and investor review.

Who will represent Satellos (MSLE) at the April 2026 Bloom Burton investor meetings?

CEO Frank Gleeson and CFO Liz Williams will represent Satellos at the conference. According to the company, Gleeson will present on April 21 and both executives will participate in scheduled one-on-one investor meetings April 21-22.

What topics will Satellos (MSLE) likely cover in its April 21, 2026 presentation?

The presentation will cover recent company developments and clinical-stage programs for degenerative muscle diseases. According to the company, the session is intended to update investors on pipeline progress and corporate strategy.

Where and when is the 2026 Bloom Burton & Co. Healthcare Investor Conference that Satellos (MSLE) will attend?

The conference runs April 21-22, 2026, at the Metro Toronto Convention Centre. According to the company, Satellos’ presentation is scheduled for April 21 with additional investor meetings across both conference days.

Will a replay of the Satellos (MSLE) April 21 presentation be available after the conference?

Yes, a replay will be posted after the live event on the company’s Events and Presentations page. According to the company, the replay will allow investors to view the presentation after the April 21 session concludes.

Keep reading